breast-cancer-2017-scientifictracks-abstracts

25 / 26

Page 62
Notes:
conferenceseries.com
Volume 2, Issue 3 (Suppl) Breast Can Curr Res, an open access journal
ISSN: 2572-4118 Breast Cancer 2017
June 15-17, 2017
June 15-17, 2017 London, UK
5th World Congress on
Breast Cancer
Oncogenic protein kinase D regulating networks in invasive breast cancer
Yan Liu1, 2, Jian Li1, Jun Zhang1, 2, Shiyi Yu1, 2, Lele Wu1, 2, Yuzhi Wang 1, 2, Xue Gong1, 2, Chenxi Wu1, 2, Xiuxiu Cai1, 2, Lin Mo3, Mingya Wang1, Jun Gu 3,
Zhenghong Yu3 and Liming Chen1, 2
1Southeast University, China
2Nanjing Normal University, China
3Medical School of Nanjing University, China
Invasive breast cancer is the leading cause of women mortality. Protein kinase D2 (PRKD2) and PRKD3 but not PRKD1, were
implicated to positively contribute to invasive breast cancer growth and progression. In current study, we found that PRKD2
and PRKD3 function as important oncogenic drivers in invasive breast cancer with evidences showing that PRKD2 and PRKD3
were preferentially expressed in invasive breast cancer cells and tissues to promote breast cancer growth in vitro and in vivo.
To uncover the molecular mechanisms of PRKD2 and PRKD3 in invasive breast cancer, phosphoproteome, interactome and
transcriptome of PRKD2 and PRKD3 were systematically investigated. Besides identification of PRKD2 and PRKD3 regulated
phosphoproteins, interacting proteins and target genes expression, 36 hub nodes including known breast cancer drivers, such
as TP53, MYC and BRCA1, were identified in PRKD2 and PRKD3 regulating networks. ELAVL1 and UBC were recognized
as the most common hub nodes across PRKDs networks. The enriched pathway analysis reveals that PRKD2 and PRKD3
regulated pathways contribute to multiple cancer related events, including cell cycle, apoptosis, migration, angiogenesis, cancer
energy metabolism and cancer immunity. Enrichment of cell cycle and cell mobility related pathways across PRKDs networks,
explained the observations that depletion of PRKD2 or PRKD3 or both or inhibition of PRKDs activity led to alternation of
cancer cell cycle and decrease of cancer cell migration ability. Besides common features, notable variations were also observed
from phosphoproteome, interactome to transcriptome between PRKD2 and PRKD3, indicating that PRKD2 and PRKD3
have shared specific functions and mechanisms. Finally, our studies raised promising invasive breast cancer therapeutic drug
targets, such as ELAVL1, Ubiquitin system, HDACs and so on. Taken together, the important roles as well as the molecular
mechanisms of PRKD2 and PRKD3 in invasive breast cancer were uncovered to provide clues for further combating invasive
breast cancer.
Biography
Liu Yan was born in Shandong province, China in 1989. He obtained B.S in Bioscience from Northeast Agriculture University in 2012. Now he is studying PhD
degree in southeast University major in oncobiology.
Yan Liu et al., Breast Can Curr Res 2017, 2:3(Suppl)
DOI: 10.4172/2572-4118-C1-005